Market Overview

Bristol-Myers Squibb Enters 3-Year Agreement with Reckitt Benckiser Group for Over-the-Counter Medicines

Share:
Related BMY
Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients
Bristol-Myers/AbbVie Cancer Drug Gets Priority Review (Zacks)

Bristol-Myers
Squibb Company (NYSE: BMY) today announced it has entered into a
three-year collaboration agreement with Reckitt Benckiser Group plc
(OTC: RBGLY) for several of its over-the-counter medicines currently sold
across Latin America, primarily in Mexico and Brazil.

Under the terms of the collaboration agreement, Reckitt Benckiser will
pay Bristol-Myers Squibb an upfront payment in the amount of $438
million for the exclusive rights to sell, distribute and market the
following medicines for a three-year period: Picot, an antacid, Tempra,
a pain reliever and fever reducer, Micostatin, an antifungal, and
Graneodin, a cough and cold medicine, sold primarily in Mexico; and
Dermodex, an anti-rash cream, Luftal, an anti-gas medicine, and

See full press release

Posted-In: News Guidance Contracts Management

 

Related Articles (BMY)

Get Benzinga's Newsletters